---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-009723"
form_type: "8-K"
ticker: "PLSE"
cik: "0001625101"
company_name: "PULSE BIOSCIENCES, INC."
filed_at: "2025-03-28T23:59:59+00:00"
generated_at: "2026-05-24T03:05:47.971572+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Pulse Biosciences Q4 GAAP net loss widens to $19.4M; cash boosted to $118M on warrant exercises

## Summary
- GAAP net loss of $19.4M in Q4 2024 vs $11.9M a year ago; full-year loss $53.6M vs $42.2M.
- Cash and equivalents $118.0M as of Dec 31, 2024, up from $44.4M a year ago, driven by $47.9M in warrant proceeds.
- Non-GAAP net loss Q4 $10.4M vs $8.3M; full-year $36.9M vs $33.8M; costs rose on stock comp and legal settlement.
- Advanced soft tissue ablation pilot at 8 U.S. centers; expects U.S. thyroid clinical trial mid-2025.
- Treated 30 patients in European AF feasibility study for surgical clamp; over 80 patients in catheter study.

## SEC filing metadata
- accession: 0001437749-25-009723
- form_type: 8-K
- ticker: PLSE
- cik: 0001625101
- company_name: PULSE BIOSCIENCES, INC.
- filed_at: 2025-03-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1625101/000143774925009723/0001437749-25-009723-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1625101/000143774925009723/plse20241119_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-009723
- JSON: https://secwatch.observer/filing/0001437749-25-009723.json
- Plain text: https://secwatch.observer/filing/0001437749-25-009723.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.